CARLSBAD, Calif., Dec. 1, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of the Phase 3 BALANCE study for AKCEA-APOCIII-LRx in adult patients with ...

– Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events – – Results ...

(RTTNews) - Crinetics Pharmaceuticals Inc. (CRNX) has dosed the first patient in its Phase 2/3 trial of investigational drug Atumelnant for the treatment of classic congenital adrenal hyperplasia in ...

BALANCE is a Phase 1/2, first-in-disease dose escalation and expansion study of ALPN-101 in patients with active, steroid-refractory or steroid-resistant acute GVHD. It will explore the safety, ...

Georgia Power, in partnership with Switched Source and ARPA-E, has installed the Phase-EQ device in Macon to increase power line capacity by up to 20%, reduce load and voltage imbalances, and enhance ...